title: Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
abstract: In order to improve brain uptake of nanoparticles following nasal administration, odorranalectin (OL), the smallest lectin with much less immunogenicity than other members of lectin family, was conjugated to the surface of poly (ethylene glycol)-poly (lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NP) in this study. The bioactivity of OL conjugated to the nanoparticles was verified by haemagglutination tests.Tissue distribution of OL-modified and unmodified nanoparticles (OL-NP and NP) was evaluated following intranasal (i.n.) administration by in vivo fluorescence imaging technique using DiR as a tracer, comparing with that of unmodified nanoparticles after intravenous (i.v.) injection. Besides, the nasal toxicity of OL-NP was evaluated on Calu-3 cell lines, toad palate and rat nasal mucosa.The results of TEM examination and dynamic light scattering showed a generally spherical shape of OL-NP with an average volume-based diameter around 90 nm. The haemagglutination test proved that OL retained its haemagglutination activity when conjugated to nanoparticles. The brain targeting indexes of NP and OL-NP following i.n. administration and NP following i.v. injection were 5.8, 11.6 and 0.08, respectively.Thus,i.n. administration demonstrated much better brain targeting efficiency than i.v. injection, and OL modification facilitated the nose-to-brain delivery of nanoparticles.Moreover, the toxicity assessment suggested good safety of OL-NP both in vitro and in vivo. In summary, odorranalectin-conjugated nanoparticle could be potentially used as a nose-to-brain drug delivery carrier for the treatment of CNS diseases.
authors.affiliation: Department of Pharmaceutical Science, School of Pharmacy, Fudan University, Shanghai 0086201203, China.
authors.forename: Ziyi
authors.initials: Z
authors.lastname: Wen
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Yan
authors.forename: Rui
authors.initials: R
authors.lastname: He
authors.forename: Zhiqing
authors.initials: Z
authors.lastname: Pang
authors.forename: Liangran
authors.initials: L
authors.lastname: Guo
authors.forename: Yong
authors.initials: Y
authors.lastname: Qian
authors.forename: Xinguo
authors.initials: X
authors.lastname: Jiang
authors.forename: Liang
authors.initials: L
authors.lastname: Fang
mesh_terms: D000281:Administration, Intranasal; D000825:Animal Structures / Q000033:anatomy & histology / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D000818:Animals; D001001:Anura; D019540:Area Under Curve; D001921:Brain / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002923:Cilia / Q000187:drug effects; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods*; D005456:Fluorescent Dyes / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D006386:Hemagglutination Tests; D006801:Humans; D007275:Injections, Intravenous; D037102:Lectins / Q000737:chemistry* / Q000494:pharmacology / Q000633:toxicity*; D046529:Microscopy, Electron, Transmission; D009061:Mouth Mucosa / Q000033:anatomy & histology / Q000187:drug effects; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity* / Q000648:ultrastructure; D009297:Nasal Mucosa / Q000033:anatomy & histology / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010159:Palate / Q000033:anatomy & histology / Q000187:drug effects; D010316:Particle Size; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
chemical_list: D005456:Fluorescent Dyes; D037102:Lectins; C530911:odorranalectin, Odorrana grahami; D010751:Phosphopyruvate Hydratase